The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
暂无分享,去创建一个
E. Felip | R. Rosell | Jia Wei | M. Taron | M. Ono | T. Bivona | R. García-Campelo | A. Giménez-Capitán | N. Karachaliou | R. Gervais | E. Carcereny | T. Morán | A. Drozdowskyj | M. Molina | M. Majem | S. Viteri | C. Costa | P. Giannikopoulos | J. Bertran-Alamillo | B. Massutí